Table 3.
Baseline characteristics and treatment response in 37 patients treated with peginterferon, ribavirin, and telaprevir according to IFNL4 ss469415590 variant.
| IFNL4 major, n = 24 | IFNL4 minor, n = 13 | P values (major versus minor groups) | |
|---|---|---|---|
| Gender, male/female | 19/5 | 9/4 | 0.78 |
| Age, years | 59.5 ± 7.7 | 55.2 ± 10.2 | 0.15 |
| Previous treatment: naïve/relapse/null | 10/13/1 | 7/4/2 | 0.71 |
| AST, IU/L | 50.9 ± 48.9 | 59.8 ± 44.2 | 0.58 |
| ALT, IU/L | 63.8 ± 60.5 | 77.9 ± 77.2 | 0.54 |
| γ-GTP, IU/L | 51.8 ± 52.2 | 78.6 ± 73.3 | 0.25 |
| Hemoglobin, g/dL | 14.6 ± 1.2 | 14.5 ± 1.3 | 0.81 |
| Platelets, ×104/mm3 | 15.9 ± 5.2 | 16.5 ± 5.3 | 0.74 |
| HCV RNA (logIU/mL) | 6.70 ± 0.54 | 6.18 ± 0.87 | 0.0309 |
| Treatment response | |||
| RVR, n | 17 | 8 | 0.83 |
| EVR, n | 22 | 10 | 0.45 |
| SVR/relapse/null | 22 | 8 | 0.0727 |
Null: null response; AST: aspirate aminotransferase; ALT: alanine aminotransferase; γ-GTP: γ-glutamyltransferase; RVR: rapid virological response; EVR: early virological response; SVR: sustained virological response.